← Back to Search

COPDE for Diabetes (PREVENT Trial)

Phase 3
Waitlist Available
Led By Barry w Rovner
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

PREVENT Trial Summary

This trial will compare the PREVENT intervention to intensive home-based diabetes education (EUC) to see if PREVENT can reduce diabetes-related emergency department visits and/or hospitalizations.

Eligible Conditions
  • Diabetes

PREVENT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
number of incident diabetes-related ED visits and/or hospitalizations
Secondary outcome measures
Actual access to care
Diabetes self-care behaviors
Perceived access to health care

PREVENT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: COPDEExperimental Treatment1 Intervention
Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
Group II: Intensive Diabetes EducationActive Control1 Intervention
In-home diabetes education

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
445 Previous Clinical Trials
145,558 Total Patients Enrolled
3 Trials studying Diabetes
600 Patients Enrolled for Diabetes
Barry w RovnerPrincipal InvestigatorThomas Jefferson University

Media Library

COPDE Clinical Trial Eligibility Overview. Trial Name: NCT03466866 — Phase 3
Diabetes Research Study Groups: COPDE, Intensive Diabetes Education
Diabetes Clinical Trial 2023: COPDE Highlights & Side Effects. Trial Name: NCT03466866 — Phase 3
COPDE 2023 Treatment Timeline for Medical Study. Trial Name: NCT03466866 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~25 spots leftby Apr 2025